Int J Psychiatry Clin Pract. 2002;6(3):163-5. doi: 10.1080/136515002760276090.
Olanzapine oro-dispersible (Velotab TM ) was introduced to the United Kingdom in May 2000. It rapidly dissolves in the mouth, and therefore patients may find it preferable to swallowing tablets. Another advantage is that the opportunity to hide the medication is much reduced. The study examined the usage of Velotab TM in a forensic psychiatry setting.
Drug expenditure for different classes of antipsychotic was examined for 6 months before and 7 months after the introduction of olanzapine Velotab TM .
The results showed a change in prescribing practice, with a significant inverse correlation between the use of Velotab TM and depot medication.
This suggests that forensic psychiatrists, who may have particular concerns about compliance, had confidence in oro-dispersible administration as an alternative to depot medication. It is suggested that making other neuroleptics available in an oro-dispersible form would allow for a wider choice of atypicals in populations in whom there are significant compliance problems. (Int J Psych Clin Pract 2002; 6: 163-165).
奥氮平口腔崩解片（商品名：再普乐）于 2000 年 5 月在英国上市。它在口中迅速溶解，因此患者可能觉得它比吞服片剂更方便。另一个优点是，隐藏药物的机会大大减少。本研究考察了奥氮平口腔崩解片在法医精神病学环境中的使用情况。
考察了奥氮平口腔崩解片上市前 6 个月和上市后 7 个月期间不同类别的抗精神病药物的药物支出。
结果显示了处方实践的变化，奥氮平口腔崩解片的使用与长效药物的使用呈显著负相关。
这表明，可能特别关注依从性的法医精神病学家对口腔崩解剂作为长效药物的替代方案有信心。建议以口腔崩解形式提供其他神经阻滞剂，以便在存在严重依从性问题的人群中为使用非典型药物提供更广泛的选择。（《国际心理临床实践杂志》2002 年；6 期：163-165）
